Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pazopanib monotherapy in platinum-resistant advanced ovarian cancer
2010-020439-38Phase 2Active
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoint: Clinical benefit rate. Started Jul 2010; status: active.
02
Drugs
pazopanib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2010-020439-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020439-38.